January 24, 2024 09:59 AM EST

LB Pharmaceuticals closes $75M Series C as it begins PhII schizophrenia trial

Kyle LaHucik

Senior Reporter

LB Pharmaceuticals, a schizophrenia biotech developing a new version of a decades-old medicine, has closed a $75 million Series C raise and it began a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

LB Pharmaceuticals closes $75M Series C as it begins PhII schizophrenia trial

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

LB Phar­ma­ceu­ti­cals clos­es $75M Se­ries C as it be­gins PhII schiz­o­phre­nia tri­al

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

LB Pharmaceuticals closes $75M Series C as it begins PhII schizophrenia trial